inclusion criteria: * eligibility for study enrollment includes meeting all the following criteria: provision of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy). stated willingness to comply with all study procedures and availability for the duration of the study. male or female aged 18-85. covid-19 positive as defined by positive reverse transcriptase polymerase chain reaction (rt-pcr) sars-cov-2 determination \< 3 days prior to day of randomization. must have mild or moderate covid-19 as consistent with nih definition: mild covid-19: individuals who have any of the various signs and symptoms of covid-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging. moderate covid-19: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (spo2) ≥94% on room air at sea level. duration of illness from acute covid-19 symptom onset must be 10 days or less. only subjects who are not at high risk for progression to severe covid-19 will be included in the study. see exclusion criterion #6. subjects who received covid-19 vaccination are eligible for the study if it is more than 28 days since the last dose of vaccination. covid-19 vaccination is not necessary for inclusion. all subjects will need be on \< 5 l o2/min to be included or on no oxygen to be enrolled in this study. if the candidate is either male or female of reproductive potential, he or she must agree to use of double barrier method of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. the duration of required usage of double barrier method or maintenance of abstinence must include the time from the beginning of the screening period until 90 days following the last dose of the study treatment.

inclusion criteria: * eligibility for study enrollment includes meeting all the following criteria: provision of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy). stated willingness to comply with all study procedures and availability for the duration of the study. male or female aged 18-85. covid-19 positive as defined by positive reverse transcriptase polymerase chain reaction (rt-pcr) sars-cov-2 determination \< 3 days prior to day of randomization. must have mild or moderate covid-19 as consistent with nih definition: mild covid-19: individuals who have any of the various signs and symptoms of covid-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging. moderate covid-19: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (spo2) ≥94% on room air at sea level. duration of illness from acute covid-19 symptom onset must be 10 days or less. only subjects who are not at high risk for progression to severe covid-19 will be included in the study. see exclusion criterion #6. subjects who received covid-19 vaccination are eligible for the study if it is more than 28 days since the last dose of vaccination. covid-19 vaccination is not necessary for inclusion. all subjects will need be on \< 5 l o2/min to be included or on no oxygen to be enrolled in this study. if the candidate is either male or female of reproductive potential, he or she must agree to use of double barrier method of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. the duration of required usage of double barrier method or maintenance of abstinence must include the time from the beginning of the screening period until 90 days following the last dose of the study treatment.

inclusion criteria: eligibility for study enrollment includes meeting all the following criteria: provision of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy). stated willingness to comply with all study procedures and availability for the duration of the study. male or female aged 18-85. covid-19 positive as defined by positive reverse transcriptase polymerase chain reaction (rt-pcr) sars-cov-2 determination < 3 days prior to day of randomization. must have mild or moderate covid-19 as consistent with nih definition: mild covid-19: individuals who have any of the various signs and symptoms of covid-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging. moderate covid-19: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (spo2) ≥94% on room air at sea level. duration of illness from acute covid-19 symptom onset must be 10 days or less. only subjects who are not at high risk for progression to severe covid-19 will be included in the study. see exclusion criterion #6. subjects who received covid-19 vaccination are eligible for the study if it is more than 28 days since the last dose of vaccination. covid-19 vaccination is not necessary for inclusion. all subjects will need be on < 5 l o2/min to be included or on no oxygen to be enrolled in this study. if the candidate is either male or female of reproductive potential, he or she must agree to use of double barrier method of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. the duration of required usage of double barrier method or maintenance of abstinence must include the time from the beginning of the screening period until 90 days following the last dose of the study treatment.

inclusion criteria: eligibility for study enrollment includes meeting all the following criteria: provision of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy). stated willingness to comply with all study procedures and availability for the duration of the study. male or female aged 18-85. covid-19 positive as defined by positive reverse transcriptase polymerase chain reaction (rt-pcr) sars-cov-2 determination < 3 days prior to day of randomization. must have mild or moderate covid-19 as consistent with nih definition: mild covid-19: individuals who have any of the various signs and symptoms of covid-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging. moderate covid-19: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (spo2) ≥94% on room air at sea level. duration of illness from acute covid-19 symptom onset must be 10 days or less. only subjects who are not at high risk for progression to severe covid-19 will be included in the study. see exclusion criterion #6. subjects who received covid-19 vaccination are eligible for the study if it is more than 28 days since the last dose of vaccination. covid-19 vaccination is not necessary for inclusion. all subjects will need be on < 5 l o2/min to be included or on no oxygen to be enrolled in this study. if the candidate is either male or female of reproductive potential, he or she must agree to use of double barrier method of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. the duration of required usage of double barrier method or maintenance of abstinence must include the time from the beginning of the screening period until 90 days following the last dose of the study treatment.